Ticker Details
Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
IPO Date:	July 6, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$10.97B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 3.26%
Avg Daily Range (30 D):	$1.76 | 2.51%
Avg Daily Range (90 D):	$1.55 | 2.35%

Institutional Daily Volume
Avg Daily Volume:	.83M
Avg Daily Volume (30 D):	1.44M
Avg Daily Volume (90 D):	2.01M

Trade Size
Avg Trade Size (Sh.):	115
Avg Trade Size (Sh.) (30 D):	49
Avg Trade Size (Sh.) (90 D):	62

Institutional Trades
Total Institutional Trades:	6,074
Avg Institutional Trade:	$3.82M
Avg Institutional Trade (30 D):	$5.61M
Avg Institutional Trade (90 D):	$6.77M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$6.51M
Avg Closing Trade (30 D):	$19.92M
Avg Closing Trade (90 D):	$24.02M
Avg Closing Volume:	192.16K

News

Apr 30, 2026 @ 5:00 PM Complement Inhibitors Market Outlook Remains Stron... Source: Delveinsight

Apr 29, 2026 @ 5:00 PM IgA Nephropathy Market Forecast to 2036: Novel The... Source: Delveinsight

Feb 13, 2026 @ 6:45 PM CRISPR Therapeutics Spotlights Momentum For Lead G... Source: Vandana Singh

Feb 9, 2026 @ 6:00 PM Idiopathic Pulmonary Fibrosis Clinical Trials & Pi... Source: Delveinsight

Jan 6, 2026 @ 3:32 PM Arrowhead Obesity Drugs Show Significant Fat Loss ... Source: Vandana Singh

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-2.17	$-.93	$.22
Diluted EPS	$-2.17	$-.93	$.22
Revenue	$622.01M	$73.74M	$264.03M
Gross Profit
Net Income / Loss	$-271.86M	$-137.57M	$28.24M
Operating Income / Loss	$-221.9M	$-141.26M	$40.81M
Cost of Revenue
Net Cash Flow	$1.24M	$-14.23M	$-24.91M
PE Ratio

Splits
Nov 17, 2011	1:10
Jan 15, 2004	1:65